NYSEArca - Delayed Quote USD

Invesco Biotechnology & Genome ETF (PBE)

60.39 +0.54 (+0.90%)
At close: April 26 at 3:37 PM EDT
59.32 -1.06 (-1.76%)
After hours: April 26 at 4:04 PM EDT

Top 10 Holdings (46.40% of Total Assets)

SymbolCompany% Assets
NBIX
Neurocrine Biosciences, Inc. 5.14%
GILD
Gilead Sciences, Inc. 5.03%
REGN
Regeneron Pharmaceuticals, Inc. 5.02%
AMGN
Amgen Inc. 4.96%
TECH
Bio-Techne Corporation 4.95%
VRTX
Vertex Pharmaceuticals Incorporated 4.91%
BMRN
BioMarin Pharmaceutical Inc. 4.87%
BIIB
Biogen Inc. 4.86%
MNKD
MannKind Corporation 3.39%
COLL
Collegium Pharmaceutical, Inc. 3.26%

Sector Weightings

SectorPBE
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Stocks 99.91%
Bonds 0.00%

Equity Holdings

Price/Earnings 0.04
Price/Book 0.22
Price/Sales 0.18
Price/Cashflow 0.05
Median Market Cap --
3 Year Earnings Growth --

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

ETF Summary

The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

ETF Overview

Category Health
Fund Family Invesco
Net Assets 245.86M
YTD Daily Total Return -8.25%
Yield 0.06%
Legal Type Exchange Traded Fund

Related Tickers